Skip to main content
Equibles
IDXGD logo

IDXGD · Interpace Biosciences, Inc.

Track IDXGD — free

Use IDXGD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IDXGD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.45 +0.00 (+0.00%) At close · Sep 18
Rebalance outlook locked
Market Cap
$178.67M
Shares
27.70M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$6.45 Open$6.65 Day$6.45–6.65 52W close$0.82–7.62 Avg vol 30d7K Short int2 · 0.0% float · 1.0d Short vol20% Last earningsJan 20, 2021 DataJul 2024–Sep 2026 Filing10-Q · Aug 10

Up next

Latest filing: 10-Q
filed Aug 10, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$36.14M
Trailing 12 months
Net income (TTM)
$24.45M
Trailing 12 months
Revenue growth YoY
-1.1%
Year over year
Operating margin
11.5%
Trailing 12 months
P / E (TTM)
6.4
Trailing earnings · reciprocal yield 15.7%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+526.6%
Year over year · more shares
Price change (1Y)
+686.6%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.8 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +227%
above
Price vs 50-day avg +114%
above
RSI (14) 71
overbought
MACD trend Negative
52-week position 83%
mid-range
Volume (OBV) Bearish div.
distributing
Momentum
relative strength
Very Strong
1-month return +303%
trailing
6-month return +279%
trailing
YTD return +424%
this year
Relative strength +259%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow Distributing
-77% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.00% of float · ▼ -97.8% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
3 holders — near 1-yr low, contrarian setup
Squeeze score 22
low risk · 0–100
Fundamentals
Strong
Revenue growth −31%
Y/Y
Gross margin 425%
expanding
EPS growth +123%
Y/Y
Free cash flow $5.5M
Quant / Vol
risk profile
Very High
Volatility 436%
annualized · 1-yr
Max drawdown −38%
past year
ATR 5.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed May 14, 2026
Thyroid revenue growth · 2026 16%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
3 · 2 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+227% Bullish
Price vs 50-day avg
+114% Bullish
RSI (14)
71 Bearish
MACD trend
Negative Bearish
52-week position
83% Neutral
Volume (OBV)
Bearish div. Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow Distributing
-77% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.00% of float · ▼ -97.8% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
3 holders — near 1-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1 Now $6 · 83% Range high $8
vs 200-day avg +227% vs 50-day avg +114%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IDXGD
Interpace Biosciences, Inc.
this stock
$178.67M +424.4% -30.7% — 0.0%
TMO
Thermo Fisher Scientific Inc.
 $240.87B +12.4% +14.5% 35.0 1.5%
DHR
Danaher Corp /De/
 $147.37B -7.5% +8.5% 37.2 1.4%
NTRA
Natera, Inc.
 $53.25B +61.2% -2.8% — 3.8%
IQV
Iqvia Holdings Inc.
 $44.71B +18.2% +41.6% 33.3 2.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
3
% held
0.0%
Net QoQ
-248.6K sh
Top holder
HRT FINANCIAL LP
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
2
Days to cover
1.0d
Change
-89 sh
View
Short Volume
Short vol %
20%
As of
Sep 14, 2026
Short Total
View
Financials
Financials
Revenue (FY)
$38.7M
Net income (FY)
$24.6M
EPS diluted
$0.89
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 27, 2026
This year
12
View
Exempt Offerings
Offering
$47.0M
Filed
Oct 16, 2024
View
Earnings & Events
Earnings Calls
Last call
Jan 20, 2021
View

Performance

5D 20D 120D MTD YTD
IDXGD -0.8% +303.1% +279.4% -14.8% +424.4%
SPY -0.3% -0.1% +20.1% -0.7% +11.7%
vs SPY -0.4% +303.2% +259.3% -14.1% +412.7%
Key facts CIK 1054102 Visit website Investor relations